JDD March Issue Highlights

March JDD
These are the issue highlights from the March issue of the JDD!

 

Azelaic acid 15% foam may be an efficacious therapy for rosacea while also offering a better side effect profile in Rosacea Treatment Satisfaction: Matching Adjusted Indirect Treatment Comparison Analysis of Metronidazole Gel or Cream vs Azelaic Acid Foam.
 
Nail Surgery Myths and Truths dispels common myths encountered by dermatologists when performing nail surgery.
Tazarotene 0.045% lotion, is effective and well-tolerated in patients with moderate-to-severe acne in Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis.
 
A 12month clinical study focuses on photoprotection for phototype IV-V patients in Long-Term Benefits of Daily Photo-Protection With a Broad-Spectrum Sunscreen in US Hispanic Female Population.
 
 
Atopic Dermatitis: A Review of Current Diagnostic Criteria and a Proposed Update to Management presents an updated, simplified set of diagnostic criteria for AD.
 

 

The Effects of Primary Defect Characteristics on Reconstruction Type and Adjunctive Intervention in Mohs Micrographic Surgery: A Retrospective Review may help counsel patients of the potential need for adjunctive cosmetic procedures following surgical repair of facial Mohs defects.

 

Efficacy and Safety of Systemic Treatments for Skin and Joint Manifestations in Patients With PsoriasisData from the British Association of Dermatologists Biologic Interventions Register (BADBIR) considers all aspects of the disease that have the greatest impact on the patient’s everyday life.

 

Treatment of Impetigo in the Pediatric Population: Consensus and Future Directions explores the use of newer safe and effective topical antibiotic for impetigo in children.

 

Field Therapy in Solid Organ Transplant Recipients: Are We Initiating Early Enough? illuminates the lack of field therapy use in organ transplant recipients with low NMSK burden compared to those with a high burden.

 

Real World SB4 (Etanercept Biosimilar) Use in Patients with Psoriasis: Data from the Registry reports on the efficacy and Safety of biosimilars in Psoriasis.